Your institution may have access to this item. Find your institution then sign in to continue.
Title
Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Authors
Castelli-Haley, Jane; Oleen-Burkey, MerriKay; Lage, Maureen J; Johnson, Kenneth P
Abstract
We compared the outcomes of multiple sclerosis (MS) patients treated with either glatiramer acetate (GA) (Copaxone, Teva Pharmaceutical Industries, Israel) or interferon beta-1a for subcutaneous administration (IFN beta-1a-SC) (Rebif, Merck Serono, Switzerland).